CAM
CORT icon

Claret Asset Management’s Corcept Therapeutics CORT Stock Holding History

Claret Asset Management’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$227K Buy
+2,606
New +$157K 0.02% 328
2025
Q4 		– Sell
-3,264
Closed -$271K – 392
2025
Q3 		$271K Buy
+3,264
New +$236K 0.03% 198

Other funds holding CORT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PA
Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Claret Asset Management's CORT Position: Q2 2026 in Review

Claret Asset Management opened a new position in Corcept Therapeutics (CORT) in Q2 2026: 2,606 shares worth $227K. The stake represents 0.02% of the portfolio and ranks #328 among its holdings. This is a return to the name: Claret Asset Management previously reported a position in CORT as recently as Q3 2025.

Claret Asset Management first reported a position in CORT in Q3 2025 and has held it in 2 quarters since. The position peaked at $271K in Q3 2025. 423 funds tracked by Wall St. Rank hold CORT as of Q2 2026.

  • Claret Asset Management held 2,606 shares of Corcept Therapeutics worth $227K as of Q2 2026.
  • Corcept Therapeutics was a new Claret Asset Management position in Q2 2026.
  • Corcept Therapeutics made up 0.02% of Claret Asset Management's portfolio in Q2 2026, its #328 holding.
  • Claret Asset Management first reported a position in Corcept Therapeutics in Q3 2025 and has held it in 2 quarters since.
  • Claret Asset Management's Corcept Therapeutics position peaked at $271K in Q3 2025.
  • 423 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q2 2026.

Based on Claret Asset Management's 13F filing for Q2 2026, filed 27 Jul 2026.